Genetics of Psoriasis

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 1-11

  Mahil, Satveer K ^a   Capon, Francesca ^b   Barker, Jonathan N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Genetics; Genome wide association studies; Psoriasis; Stratification

Indexed keywords

METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HERITABILITY; HUMAN; IMMUNOGENETICS; IMMUNOPATHOLOGY; INNATE IMMUNITY; LINKAGE ANALYSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; PERMEABILITY BARRIER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROGNOSIS; PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; GENETICS; IMMUNOLOGY;

ADAPTIVE IMMUNITY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; PSORIASIS; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 84911485577     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.001     Document Type: Review

References (87)

1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. NEngl J Med 2009, 361(5):496-509.
2. Elder J.T., Nair R.P., Guo S.W., et al. The genetics of psoriasis. Arch Dermatol 1994, 130(2):216-224.
3. Lomholt G. Psoriasis: prevalence, spontaneous course and genetics: a census study on the prevalence of skin disease on the Faroe Islands 1963, G. E. C Gad, Copenhagen, Denmark.
4. Morris A., Rogers M., Fischer G., et al. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001, 18(3):188-198.
5. Brandrup F., Hauge M., Henningsen K., et al. Psoriasis in an unselected series of twins. Arch Dermatol 1978, 114(6):874-878.
6. Duffy D.L., Spelman L.S., Martin N.G. Psoriasis in Australian twins. JAm Acad Dermatol 1993, 29(3):428-434.
7. Farber E.M., Nall M.L., Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974, 109(2):207-211.
8. Gudjonsson J.E., Elder J.T. Psoriasis: epidemiology. Clin Dermatol 2007, 25(6):535-546.
9. Witte J.S., Elston R.C., Schork N.J. Genetic dissection of complex traits. Nat Genet 1996, 12(4):355-356. [author reply: 357-8].
10. Lander E.S. The new genomics: global views of biology. Science 1996, 274(5287):536-539.
11. Reich D.E., Lander E.S. On the allelic spectrum of human disease. Trends Genet 2001, 17(9):502-510.
12. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997, 6(5):813-820.
13. Nair R.P., Henseler T., Jenisch S., et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997, 6(8):1349-1356.
14. Veal C.D., Capon F., Allen M.H., et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 2002, 71(3):554-564.
15. Capon F., Munro M., Barker J., et al. Searching for the major histocompatibility complex psoriasis susceptibility gene. JInvest Dermatol 2002, 118(5):745-751.
16. Nair R.P., Stuart P.E., Nistor I., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006, 78(5):827-851.
17. Hundhausen C., Bertoni A., Mak R.K., et al. Allele-specific cytokine responses at the HLA-C locus: implications for psoriasis. JInvest Dermatol 2012, 132(3 Pt 1):635-641.
18. Clop A., Bertoni A., Spain S.L., et al. An in-depth characterization of the major psoriasis susceptibility locus identifies candidate susceptibility alleles within an HLA-C enhancer element. PLoS One 2013, 8(8):e71690.
19. Cortes A., Brown M.A. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011, 13(1):101.
20. Ellinghaus E., Ellinghaus D., Stuart P.E., et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010, 42(11):991-995.
21. Ellinghaus D., Ellinghaus E., Nair R.P., et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012, 90(4):636-647.
22. Nair R.P., Duffin K.C., Helms C., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41(2):199-204.
23. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A., Capon F., et al. Agenome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010, 42(11):985-990.
24. Stuart P.E., Nair R.P., Ellinghaus E., et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010, 42(11):1000-1004.
25. Sun L.D., Cheng H., Wang Z.X., et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010, 42(11):1005-1009.
26. Zhang X.J., Huang W., Yang S., et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009, 41(2):205-210.
27. De Cid R., Riveira-Munoz E., Zeeuwen P.L., et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009, 41(2):211-215.
28. Tsoi L.C., Spain S.L., Knight J., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012, 44(12):1341-1348.
29. Nair R.P., Ruether A., Stuart P.E., et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. JInvest Dermatol 2008, 128(7):1653-1661.
30. Cargill M., Schrodi S.J., Chang M., et al. Alarge-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80(2):273-290.
31. Nair R.P., Stuart P.E., Kullavanijaya P., et al. Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. Arch Dermatol Res 2010, 302(2):139-143.
32. Wu Y., Lu Z., Chen Y., et al. Replication of association between interleukin-23 receptor (IL-23R) and its ligand (IL-12B) polymorphisms and psoriasis in the Chinese Han population. Hum Immunol 2010, 71(12):1255-1258.
33. Capon F., Di Meglio P., Szaub J., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007, 122(2):201-206.
34. Duerr R.H., Taylor K.D., Brant S.R., et al. Agenome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314(5804):1461-1463.
35. Rueda B., Orozco G., Raya E., et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008, 67(10):1451-1454.
36. Di Meglio P., Di Cesare A., Laggner U., et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011, 6(2):e17160.
37. Di Meglio P., Villanova F., Napolitano L., et al. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. JInvest Dermatol 2013, 133(10):2381-2389.
38. Lee E., Trepicchio W.L., Oestreicher J.L., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. JExp Med 2004, 199(1):125-130.
39. Hüffmeier U., Uebe S., Ekici A.B., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010, 42(11):996-999.
40. Wang C., Wu L., Bulek K., et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013, 14(1):72-81.
41. Mischke D., Korge B.P., Marenholz I., et al. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. JInvest Dermatol 1996, 106(5):989-992.
42. Capon F., Semprini S., Dallapiccola B., et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet 1999, 65(6):1798-1800.
43. Capon F., Novelli G., Semprini S., et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. JInvest Dermatol 1999, 112(1):32-35.
44. Bergboer J.G., Tjabringa G.S., Kamsteeg M., et al. Psoriasis risk genes of the late cornified envelope-3 group are distinctly expressed compared with genes of other LCE groups. Am J Pathol 2011, 178(4):1470-1477.
45. Bergboer J.G., Zeeuwen P.L., Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. JInvest Dermatol 2012, 132(10):2320-2321.
46. Garber K. Genetics: deep exploration. Nature 2012, 492(7429):S56-S57.
47. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30(8):383-391.
48. Jordan C.T., Cao L., Roberson E.D., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012, 90(5):784-795.
49. Jordan C.T., Cao L., Roberson E.D., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012, 90(5):796-808.
50. Capon F., Bijlmakers M.J., Wolf N., et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 2008, 17(13):1938-1945.
51. Bijlmakers M.J., Kanneganti S.K., Barker J.N., et al. Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet 2011, 20(16):3129-3137.
52. Prens E.P., Kant M., van Dijk G., et al. IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis. JInvest Dermatol 2008, 128(4):932-938.
53. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461(7265):788-792.
54. Hollox E.J., Huffmeier U., Zeeuwen P.L., et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008, 40(1):23-25.
55. Stuart P.E., Hüffmeier U., Nair R.P., et al. Association of β-defensin copy number and psoriasis in three cohorts of European origin. JInvest Dermatol 2012, 132(10):2407-2413.
56. Jansen P.A., Rodijk-Olthuis D., Hollox E.J., et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009, 4(3):e4725.
57. Hsu L.N., Armstrong A.W. Psoriasis and autoimmune disorders: a review of the literature. JAm Acad Dermatol 2012, 67(5):1076-1079.
58. Marrakchi S., Guigue P., Renshaw B.R., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. NEngl J Med 2011, 365(7):620-628.
59. Onoufriadis A., Simpson M.A., Pink A.E., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89(3):432-437.
60. Setta-Kaffetzi N., Navarini A.A., Patel V.M., et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. JInvest Dermatol 2013, 133(5):1366-1369.
61. Berki D.M., Mahil S.K., Burden A.D., et al. Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris. JInvest Dermatol 2014, 134(1):271-273.
62. Viguier M., Guigue P., Pagès C., et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010, 153(1):66-67.
63. Hüffmeier U., Wätzold M., Mohr J., et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2014, 170(1):202-204.
64. Setta-Kaffetzi N., Simpson M.A., Navarini A.A., et al. AP1S3 mutations are associated with pustular psoriasis and impaired toll-like receptor 3 trafficking. Am J Hum Genet 2014, 94(5):790-797.
65. González-Navajas J.M., Lee J., David M., et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012, 12(2):125-135.
66. Hébert H.L., Bowes J., Smith R.L., et al. Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. JInvest Dermatol 2014, 134:1459-1462.
67. Warren R.B., Smith R.L., Campalani E., et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. JInvest Dermatol 2008, 128(8):1925-1929.
68. Tejasvi T., Stuart P.E., Chandran V., et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. JInvest Dermatol 2012, 132(3 Pt 1):593-600.
69. Talamonti M., Botti E., Galluzzo M., et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013, 169(2):458-463.
70. Homepage [Internet]. PSORT. Available at: . Accessed October 10, 2014. http://www.psort.org.uk/.
71. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371(9625):1665-1674.
72. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371(9625):1675-1684.
73. Crow J.M. Therapeutics: silencing psoriasis. Nature 2012, 492(7429):S58-S59.
74. Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. NEngl J Med 2012, 366(13):1181-1189.
75. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. NEngl J Med 2012, 366(13):1190-1199.
76. Goldsmith L., Jackson L., O'Connor A., et al. Direct-to-consumer genomic testing from the perspective of the health professional: a systematic review of the literature. JCommunity Genet 2013, 4(2):169-180.
77. Lancet Oncology Black-box warning: direct-to-consumer marketing. Lancet Oncol 2014, 15(1):1.
78. Smemo S., Tena J.J., Kim K.H., et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 2014, 507(7492):371-375.
79. ENCODE Project Consortium, Bernstein B.E., Birney E., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489(7414):57-74.
80. Schaub M.A., Boyle A.P., Kundaje A., et al. Linking disease associations with regulatory information in the human genome. Genome Res 2012, 22(9):1748-1759.
81. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753.
82. Hunt K.A., Mistry V., Bockett N.A., et al. Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature 2013, 498(7453):232-235.
83. Tang H., Jin X., Li Y., et al. Alarge-scale screen for coding variants predisposing to psoriasis. Nat Genet 2014, 46(1):45-50.
84. Available at: . Accessed October 10, 2014. http://www.psoriasiscouncil.org/.
85. Zhang P., Su Y., Lu Q. Epigenetics and psoriasis. JEur Acad Dermatol Venereol 2012, 26(4):399-403.
86. Zhang P., Zhao M., Liang G., et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. JAutoimmun 2013, 41:17-24.
87. Roberson E.D., Liu Y., Ryan C., et al. Asubset of methylated CpG sites differentiate psoriatic from normal skin. JInvest Dermatol 2012, 132(3 Pt 1):583-592.